Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
2.510
+0.170 (7.26%)
At close: Apr 28, 2026, 4:00 PM EDT
2.496
-0.014 (-0.57%)
After-hours: Apr 28, 2026, 7:19 PM EDT
Context Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Context Therapeutics stock have an average target of 6.60, with a low estimate of 5.00 and a high estimate of 9.00. The average target predicts an increase of 162.95% from the current stock price of 2.51.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 24, 2026.
Analyst Ratings
The average analyst rating for Context Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +258.57% | Mar 24, 2026 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +99.20% | Mar 24, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $7 | Buy | Maintains | $4 → $7 | +178.88% | Mar 24, 2026 |
| Jones Trading | Jones Trading | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +178.88% | Dec 22, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +258.57% | Nov 6, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.46
from -0.38
EPS Next Year
-0.44
from -0.46
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.22 | -0.26 | ||||||
| Avg | -0.46 | -0.44 | ||||||
| Low | -0.61 | -0.64 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.